Journal of Vaccine Research, 2025, Vol.15, No.1, 45-55 http://medscipublisher.com/index.php/jvr 54 Conforti F., Pala L., Pagan E., Bagnardi V., De Pas T., Queirolo P., Pennacchioli E., Catania C., Cocorocchio E., Ferrucci P., Saponara M., Orsolini G., Zagami P., Nicolo, E., De Marinis F., Tortora G., Bria E., Minucci S., Joffe H., Veronesi P., Wargo J., Rosenthal R., Swanton C., Mantovani A., Gelber R., Viale G., Goldhirsch A., and Giaccone G., 2021, Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion, Clinical Cancer Research, 27(15): 4311-4324. https://doi.org/10.1158/1078-0432.CCR-21-0136 Fan T., Zhang M.N., Yang J., Zhu Z., Cao W.L., and Dong C.Y., 2023, Therapeutic cancer vaccines: advancements, challenges and prospects, Signal Transduction and Targeted Therapy, 8(1): 50. https://doi.org/10.1038/s41392-023-01674-3 García-Pardo M., Gorría T., Malenica I., Corgnac S., Teixidó C., and Mezquita L., 2022, Vaccine therapy in non-small cell lung cancer, Vaccines, 10(5): 740. https://doi.org/10.3390/vaccines10050740 Gu W.Y., Xu Y., Chen X.H., and Jiang H., 2022, Characteristics of clinical trials for non-small cell lung cancer therapeutic vaccines registered on clinicaltrials.gov, Frontiers in Immunology, 13: 936667. https://doi.org/10.3389/fimmu.2022.936667 Hannani D., Leplus E., Laurin D., Caulier B., Aspord C., Madelon N., Bourova-Flin E., Brambilla C., Brambilla E., Toffart A., Laulagnier K., Chaperot L., and Plumas J., 2023, A new plasmacytoid dendritic cell-based vaccine in combination with anti-pd-1 expands the tumor-specific CD8+T cells of lung cancer patients, International Journal of Molecular Sciences, 24(3): 1897. https://doi.org/10.3390/ijms24031897 Hong W., Xue M., Jiang J., Zhang,Y., and Gao X., 2020, Circular RNA circ-CPA4/let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC), Journal of Experimental and Clinical Cancer Research, 39(1): 149. https://doi.org/10.1186/s13046-020-01648-1 Ikeda H., Kawase K., Nishi T., Watanabe T., Takenaga K., Inozume T., Ishino T., Aki S., Lin J., Kawashima S., Nagasaki J., Ueda Y., Suzuki S., Makinoshima H., Itami M., Nakamura Y., Tatsumi Y., Suenaga Y., Morinaga T., Honobe-Tabuchi A., Ohnuma T., Kawamura T., Umeda Y., Nakamura Y., Kiniwa Y., Ichihara E., Hayashi H., Ikeda J., Hanazawa T., Toyooka S., Mano H., Suzuki T., Osawa T., Kawazu M., and Togashi Y., 2025, Immune evasion through mitochondrial transfer in the tumour microenvironment, Nature, 638(8049): 225-236. https://doi.org/10.1038/s41586-024-08439-0 Huang H., 2024, Radiotherapy innovations in lung cancer: clinical evidence and future prospects, International Journal of Clinical Case Reports, 14(5): 290-298. https://doi.org/10.5376/ijccr.2024.14.0029 Ingels J., De Cock L., Stevens D., Mayer R., Théry F., Sanchez G., Vermijlen D., Weening K., De Smet S., Lootens N., Brusseel M., Verstraete T., Buyle J., Van Houtte E., Devreker P., Heyns K., De Munter S., Van Lint S., Goetgeluk G., Bonte S., Billiet L., Pille M., Jansen H., Pascal E., Deseins L., Vantomme L., Verdonckt M., Roelandt R., Eekhout T., Vandamme N., Leclercq G., Taghon T., Kerre T., Vanommeslaeghe F., Dhondt A., Ferdinande L., Van Dorpe J., Desender L., De Ryck F., Vermassen F., Surmont V., Impens F., Menten B., Vermaelen K., and Vandekerckhove B., 2024, Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum, Cell Reports Medicine, 5(5): 101516. https://doi.org/10.1016/j.xcrm.2024.101516 Kim S.S., and Cho S.W., 2022, The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment, Frontiers in Pharmacology, 13: 868695. https://doi.org/10.3389/fphar.2022.868695 Kiousi E., Lyraraki V., Mardiki G.L., Stachika N., Damianou A.K., Malainou C.P., Syrigos N., Gomatou G., and Kotteas E., 2023, Progress and challenges of messengerRNA vaccines in the therapeutics of NSCLC, Cancers, 15(23): 5589. https://doi.org/10.3390/cancers15235589 Kjeldsen J.W., Iversen T.Z., Engell-Noerregaard L., Mellemgaard A., Andersen M.H., and Svane I., 2018, Durable clinical responses and long-term follow-up of stage III–IV non-small-cell lung cancer (NSCLC) patients treated with ido peptide vaccine in a phase I study-a brief research report, Frontiers in Immunology, 9: 2145. https://doi.org/10.3389/fimmu.2018.02145 Lahiri A., Maji A., Potdar P., Singh N., Parikh P., Bisht B., Mukherjee A., and Paul M., 2023, Lung cancer immunotherapy: progress, pitfalls, and promises, Molecular Cancer, 22(1): 40. https://doi.org/10.1186/s12943-023-01740-y Liu Z., Wang T., She Y., Wu K., Gu S., Li L., Dong C., Chen C., and Zhou Y., 2021, N6-methyladenosine-modified circIGF2BP3 inhibits CD8+T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer, Molecular Cancer, 20(1): 40. https://doi.org/10.1186/s12943-021-01398-4 Liu J.M., 2024, The role of adjuvants in enhancing cancer vaccine efficacy, Journal of Vaccine Research, 14(4): 183-195. https://doi.org/10.5376/jvr.2024.14.0018 Oliveres H., Caglevic C., Passiglia F., Taverna S., Smits E., and Rolfo C., 2018, Vaccine and immune cell therapy in non-small cell lung cancer, Journal of Thoracic Disease, 10(Suppl 13) S1602-S1614. https://doi.org/10.21037/jtd.2018.05.134 Saavedra D., and Crombet T., 2017, CIMAvax-EGF: a new therapeutic vaccine for advanced non-small cell lung cancer patients, Frontiers in Immunology, 8: 269. https://doi.org/10.3389/fimmu.2017.00269
RkJQdWJsaXNoZXIy MjQ4ODYzNA==